$Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data$

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data

Patients with heart failure with reduced ejection fraction (HFrEF), despite optimal evidence-based treatment, have a high residual risk of adverse outcomes. The favorable results of studies on cardiovascular safety and the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patient...

Full description

Bibliographic Details
Main Authors:	Zh. D. Kobalava, V. V. Medovchshikov, N. B. Yeshniyazov
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-06-01
Series:	Российский кардиологический журнал
Subjects:	heart failure reduced ejection fraction type 2 diabetes sglt2 inhibitors dapagliflozin guideline-recommended therapy dapa-hf sub-analysis
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3870

Similar Items

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
by: Minara S. Shamkhalova, et al.
Published: (2022-11-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
by: Gupta M, et al.
Published: (2021-08-01)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
by: Anna Camps-Vilaró, et al.
Published: (2020-07-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

SGLT-2 inhibitors: new effective drugs for treatment of heart failure
by: Olgierd Król, et al.
Published: (2022-12-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Results of the DAPA-CKD trial and their impact on clinical practice
by: O.V. Bilchenko
Published: (2023-06-01)

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
by: Milton Packer
Published: (2019-10-01)

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023-01-01)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study
by: Carmen Mora-Fernández, et al.
Published: (2023-08-01)

Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
by: Xizi Shen, et al.
Published: (2022-08-01)

SGLT2 inhibitors in heart failure with reduced ejection fraction
by: Uday Sankar Das, et al.
Published: (2021-10-01)

The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus
by: Zh. D. Kobalava, et al.
Published: (2019-11-01)

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
by: Nannan Zhang, et al.
Published: (2019-08-01)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
by: Glenn M. Chertow, et al.
Published: (2023-05-01)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
by: Yi Tang, et al.
Published: (2023-08-01)

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024-03-01)

Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
by: Laurent Fauchier, et al.
Published: (2023-02-01)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
by: Huzaifa Ahmad Cheema, et al.
Published: (2023-10-01)

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
by: Spyros Kolovos, et al.
Published: (2023-12-01)

SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
by: Mainak Banerjee, et al.
Published: (2023-03-01)

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
by: Ankeet S. Bhatt, et al.
Published: (2024-03-01)

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
by: Yifang GUO
Published: (2022-06-01)

Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
by: Yintang Wang, et al.
Published: (2022-12-01)

DAPA-HF study: Are the benefits uniform across non-diabetic subgroups
by: Anil Pareek, et al.
Published: (2020-09-01)

Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?
by: Jonathan C. H. Chan, et al.
Published: (2023-03-01)

SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology
by: Marta Bogowska, et al.
Published: (2023-10-01)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)

Influence of intravenous ferric carboxymaltose on non-invasive parameters of left ventricular myocardial work in patients with heart failure with reduced ejection fraction
by: Zh. D. Kobalava, et al.
Published: (2023-02-01)

Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction
by: Carlos Escobar, et al.
Published: (2023-03-01)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
by: He Lu, et al.
Published: (2023-09-01)

Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis
by: Evgeny M. Mezhonov, et al.
Published: (2023-04-01)

Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
by: Ghader Mohammadnezhad, et al.
Published: (2022-12-01)

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
by: Mayu Tochiya, et al.
Published: (2023-04-01)

Insulin Resistance Is Associated With Heart Failure With Recovered Ejection Fraction in Patients Without Diabetes
by: Chen Die Yang, et al.
Published: (2022-10-01)